A drug repurposing screen identifies altiratinib as a selective inhibitor of a key regulatory splicing kinase and a potential therapeutic for toxoplasmosis and malaria
C. SWALE, V. BELLINI, M. W. Bowler, F. NARDELLA, M.-P. Brenier-Pinchart, D. Cannella, L. Belmudes, C. MAS, Y. Coute, F. LAURENT, A. Scherf, A. BOUGDOUR, M.-a. HAKIMI
This paper identifies altiratinib as a selective inhibitor of PRP4K/CLK3 kinases in apicomplexan parasites, showing broad-spectrum antiparasitic activity against toxoplasmosis and malaria.
bioRxiv · Nov 3, 2021 · PreprintMicrobiology